A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Eisai and Biogen’s Alzheimer’s drug Leqembi has received a thumbs down from the European Medicines Agency’s expert committee, which raised concerns about safety and limited efficacy.
The news is a major setback for the two companies, as the EU is expected to be the second biggest...
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
